| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| IHC-Prediluted | NBP2-44540 | |||
| Azide and BSA Free | NBP2-34736-0.1mg | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-71691-0.1mg | |||
| BSA Free | NBP1-71691SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | MAB4597 | |||
| Carrier Free | MAB4597-SP | |||
| Carrier Free | FAB4597V-100UG | |||
| Carrier Free | FAB4597U-100UG | |||
| Carrier Free | FAB4597T-100UG | |||
| Carrier Free | FAB4597S-100UG | |||
| Carrier Free | FAB4597R-100UG | |||
| Carrier Free | FAB4597N-100UG | |||
| Carrier Free | FAB4597G-100UG | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-77477SS | |||
| BSA Free | NB100-77477-0.1mg | |||
| Azide and BSA Free | NBP2-80624 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-65906-0.025mg | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-27333 | |||
| BSA Free | NBP2-27333SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | MAB5741 | |||
| Carrier Free | MAB5741-SP | |||
| Carrier Free | FAB5741V-100UG | |||
| Carrier Free | FAB5741U-100UG | |||
| Carrier Free | FAB5741T-100UG | |||
| Carrier Free | FAB5741S-100UG | |||
| Carrier Free | FAB5741R-100UG | |||
| Carrier Free | FAB5741N-100UG | |||
| Carrier Free | FAB5741G-100UG | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-31150SS | |||
| BSA Free | NBP2-31150 | |||
| Azide and BSA Free | NBP2-80983 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-31150SS | |||
| BSA Free | NBP2-31150 | |||
| Azide and BSA Free | NBP2-80983 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | FAB3050A | |||
| Carrier Free | FAB3050G | |||
| Carrier Free | FAB3050V-100UG | |||
| Carrier Free | FAB3050U-100UG | |||
| Carrier Free | FAB3050T-100UG | |||
| Carrier Free | FAB3050S-100UG | |||
| Carrier Free | FAB3050R-100UG | |||
| Carrier Free | FAB3050N-100UG | |||
![CD68/SR-D1 Antibody (SPM130) [FITC] [NBP2-34736F] - Vial of FITC conjugated antibody. FITC is optimally excited at 498 nm by the Blue laser (488 nm) and has an emission maximum of 519 nm.](http://images.novusbio.com/fullsize/nbp2-34736f_mouse-monoclonal-cd68-sr-d1-antibody-spm130-fitc-31720238124295.jpg "CD68/SR-D1 Antibody (SPM130) [FITC] [NBP2-34736F] - Vial of FITC conjugated antibody. FITC is optimally excited at 498 nm by the Blue laser (488 nm) and has an emission maximum of 519 nm.")
![CD14 Antibody (433423) [Allophycocyanin] [FAB4597A] - Vial of APC conjugated antibody. APC is optimally excited at 650 nm by the Red laser (633 or 640 nm) and has an emission maximum of 660 nm.](http://images.novusbio.com/fullsize/fab4597a_mouse-monoclonal-cd14-antibody-433423-allophycocyanin-31720239483990.jpg "CD14 Antibody (433423) [Allophycocyanin] [FAB4597A] - Vial of APC conjugated antibody. APC is optimally excited at 650 nm by the Red laser (633 or 640 nm) and has an emission maximum of 660 nm.")
![Flow Cytometry: CD45 Antibody (YKIX716.13) [NB100-65906] - Staining of canine peripheral blood lymphocytes with rat anti-canine CD45 antibody (YKIX716.13) [NB100-65906], using F(ab')2 rabbit anti rat IgG: FITC (STAR17B) as a secondary antibody.](http://images.novusbio.com/fullsize/CD45-Antibody-YKIX716-13-Flow-Cytometry-NB100-65906-img0001.jpg "Flow Cytometry: CD45 Antibody (YKIX716.13) [NB100-65906] - Staining of canine peripheral blood lymphocytes with rat anti-canine CD45 antibody (YKIX716.13) [NB100-65906], using F(ab')2 rabbit anti rat IgG: FITC (STAR17B) as a secondary antibody.")
![Flow Cytometry: CD45 Antibody (YKIX716.13) [NB100-65906] - Immunophenotyping & multipotency assay. Representative dot plots from flow cytometry analysis (A). Expression of surface antigens were investigated in cells cultured in control & AZA/RES supplemented medium. Isolated cells were characterized by the expression of CD90 & CD44 while lacked the expression of CD45 hematopoietic marker (B). Multipotency of isolated cells was confirmed by three lineage differentiation (C). In order to confirm formation of proteoglycans during chondrogenesis cells were stained with Safranin O. Intracellular lipid droplets were visualized by Oil Red O while mineralized matrix formed during osteogenesis with Alizarin Red. Magnification ×100, scale bars: 250 μm. Results expressed as mean ± SD. Statistical significance indicated as asterisk (*) when comparing the result to ASCCTRL, & as hashtag (#) when comparing to ASCEMS. ###P < 0.001 Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30370650), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-65906_rat-monoclonal-cd45-antibody-ykix716-13-31020241612693.jpg)
![Flow Cytometry: IL-33 Antibody (6H617) [FITC] [NBP2-27333F] - An intracellular stain was performed on Jurkat cells with IL-33 [6H617] Antibody NBP2-27333F (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to FITC.](http://images.novusbio.com/fullsize/IL-33-Antibody-6H617-FITC-Flow-Cytometry-NBP2-27333F-img0001.jpg "Flow Cytometry: IL-33 Antibody (6H617) [FITC] [NBP2-27333F] - An intracellular stain was performed on Jurkat cells with IL-33 [6H617] Antibody NBP2-27333F (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to FITC.")